Comparative Network Pharmacology Analysis of Ethyl Acetate, n-Butanol and Residual Fractions of Stachytarpheta jamaicensis Against Lung Cancer
This study employs a network pharmacology framework to demonstrate that ethyl acetate, n-butanol, and residue fractions of *Stachytarpheta jamaicensis* exhibit comparable anticancer potential against lung cancer by targeting shared hub genes and kinase-mediated pathways, with the n-butanol fraction containing the most promising lead compound, Silychristin.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Lung cancer remains the most common cause of cancer death worldwide, a relentless disease that often resists standard treatments and leaves patients with very few options for long-term survival. Because cancer cells are complex and adaptable, scientists have increasingly turned their attention to plants, hoping to find compounds that can attack the disease from multiple angles at once. This approach, known as network pharmacology, operates on the idea that a single plant extract contains many different chemicals, each capable of interacting with various targets inside a cancer cell. Instead of hunting for one "magic bullet" that blocks a single pathway, researchers look for a collection of natural compounds that work together to disrupt the cancer's ability to grow and survive. The goal is to understand how these natural mixtures might offer a broader, more resilient defense against the disease than a single synthetic drug could provide.
In a recent study, researchers set out to investigate a tropical plant called Stachytarpheta jamaicensis, which has a long history of use in traditional medicine for treating inflammation and infections. While previous studies had looked at how this plant affects breast and cervical cancers, no one had examined its potential against lung cancer, nor had anyone used modern computational tools to map out exactly how its chemical components might interact with the disease. To solve this, the team took leaves from the plant and separated their chemical contents into three distinct groups based on how they dissolved in different solvents: one group captured in ethyl acetate, another in n-butanol, and a third remaining as a residue. This separation allowed them to see if one specific type of chemical was responsible for any potential anti-cancer effects, or if the power was spread across the whole mixture.
The researchers began by identifying the specific chemicals present in each of these three groups and filtering them to find those most likely to be safe and effective in the human body. They found that all three groups contained a similar number of promising compounds. When they used computer models to predict which genes these compounds might target, the results were strikingly consistent. Each of the three groups showed a very high overlap with the genes known to be involved in lung cancer, with roughly 82 to 83 percent of their predicted targets matching lung cancer genes. This finding suggested that the plant's potential to fight lung cancer is not concentrated in just one part of the extract but is a distributed property, meaning that the ethyl acetate, n-butanol, and residue fractions all contribute to the effect in a similar way.
To dig deeper, the team built a map of how these predicted targets interact with one another, looking for the most critical nodes, or "hub" genes, that hold the network together. They discovered that a gene called HIF1A was a central hub for all three groups, while four other important genes—AKT1, SRC, EGFR, and BCL2—appeared as hubs in at least two of the groups. These genes are known to be crucial in how lung cancer cells survive, grow, and resist treatment. The researchers then used molecular docking, a computer simulation that acts like a virtual lock-and-key test, to see how well the top compounds from each group fit into the structures of these five key proteins. They compared the performance of these natural compounds against known, powerful cancer drugs to ensure their measurements were accurate.
The simulations revealed that the n-butanol fraction contained the most potent candidate, a compound called Silychristin. In the virtual tests, Silychristin fit into the SRC and EGFR protein targets with a strength comparable to the standard clinical drugs dasatinib and erlotinib. Another strong contender came from the residue fraction, a compound named Secoisolariciresinol, which also showed excellent binding strength to the SRC target. Interestingly, while the HIF1A gene was a central hub in the network, the computer models showed that it did not have a suitable pocket for these compounds to bind to, highlighting that being a central player in a disease network does not always mean a protein is easy to target with a drug. The study concluded that the anticancer potential of Stachytarpheta jamaicensis is a collective effort of its various chemical fractions, with Silychristin and Secoisolariciresinol emerging as the most promising leads for future laboratory testing.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.